DVAX Stock Forecast: Table Is Being Set – Revenue Growth Is On The Way

July 8, 2018

The article was written by Amber Zhou, a Financial Analyst at I Know First.

DVAX Stock Forecast

“We believe there’s a great opportunity for Dynavax to contribute to the overall health of the adult population with diabetes”—said Dr. Rob Janssen, chief medical officer of Dynavax.

(Source: mmm-online.com)

Highlights:

Competitive Edge and Huge Market Potential from Heplisav-B^®
Market Doubts about Trial Data of Immuno-Oncology Platform
Strong Cash Position from Debt Financing
Current I Know First Bullish Forecast For DVAX

Read The Full Premium Article

Subscribe to receive exclusive PREMIUM content here

Biotech Stocks Forecast Chemicals Stocks Pharma Stocks Forecast Premium Articles

Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

June 18, 2018

Winning ENTA Stock Forecast: Enanta Pharmaceuticals shows constant promising R&D results

Enanta also has three clinical stage internally invented and wholly owned programs in areas of high unmet need namely NASH, PBC and RSV. And I would note, all three of these development programs now have fast track designation.

Jay Luly, President and CEO

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), incorporated on July 25, 1995, is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development

Pharma Stocks Forecast Winning Stock Forecast

Dynavax Stock Analysis: Low Risk and High Reward, Buy Now.

August 9, 2017

The article was written by Moises Meir, a Financial Analyst at I Know First.

Dynavax Stock Analysis: Low Risk and High Reward, Buy Now.

Summary

Dynavax has an upcoming product that will revolutionize the vaccine industry./li>
When is HEPLISAV-B's launch?
Other current projects at DVAX
Financial/Stock Performance & I Know First's Bullish Forecast

Read The Full Premium Article

Subscribe to receive exclusive PREMIUM content Here

Healthcare Premium Articles

Dynavax Stock Analysis: FDA Approval On The Horizon For DVAX Could Provide Tremendous Upside

July 2, 2017

This article was written by Zachary Shipman, a financial Analyst at I Know First.

Dynavax Stock Analysis

"If approved, this vaccine could offer a better way to protect people from a chronic infection that can cause cirrhosis of the liver, cancer or death," said Robert Janssen, MD, chief medical officer and vice president of clinical development for Dynavax.